Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Spinal Fluid
Use
The CRMP-5 IgG test is utilized for evaluation of neuroautoimmunity, particularly in conjunction with small-cell lung carcinoma and thymoma. This test detects autoantibodies specific for neurons, glia, and muscle, which are significant serological markers for neurological autoimmunity. Such markers can predict specific neoplasms and their presence in small-cell lung carcinoma, associated with various neurological manifestations such as subacute chorea, blindness, myelopathy, and others often mimicking stroke or multiple sclerosis.
Special Instructions
Not provided.
Limitations
This test cannot screen for all forms of neuroautoimmunity, as seronegativity does not rule out neoplasm presence. Low titer or presence of coexisting autoantibodies might preclude identification of CRMP-5 IgG. Coexisting non-neuron-specific autoantibodies can typically be eliminated by absorption with liver antigens.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
CRMP-5-IgG
Antibody
LOINC Codes
- 94706-9 - CV2 IgG Titr CSF IF
- 94706-9 - CV2 IgG Titr CSF IF
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
4 mL
Minimum Volume
2 mL
Container
Sterile vial
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |